Kell, Kx and the McLeod syndrome

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 4, 1999, Pages 621-635

  Redman, Colvin M ^a   Russo, David ^a   Lee, Soohee ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Blood group genotyping; Endothelin 3 converting enzyme; Fetal anaemia; Kell; McLeod syndrome; XK

Indexed keywords

BLOOD GROUP ANTIBODY; BLOOD GROUP ANTIGEN;

AMINO ACID SUBSTITUTION; ANEMIA; BLOOD GROUP KELL SYSTEM; CHROMOSOME 7Q; DISULFIDE BOND; GENE; HYPERTRANSLUCENT LUNG; PREGNANCY; PRIORITY JOURNAL; REVIEW; X CHROMOSOME;

EID: 0033499736     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0045     Document Type: Article

References (95)

1. Marsh W L, Redman C M. Recent developments in the Kell blood group system. Transfusion Medicine Reviews. 1:1987;4-20.
2. Marsh W L, Redman C M. The Kell blood group system: a review. Transfusion. 30:1990;158-167.
3. Redman C M, Marsh W L. The Kell blood group system and the McLeod phenotype. Seminars in Hematology. 30:1993;209-218.
4. Lee S. Molecular basis of Kell blood group phenotypes. Vox Sanguinis. 73:1997;1-11.
5. Lee S, Zambas E D, Marsh W L, Redman C M. Molecular cloning and primary structure of Kell blood group protein. Proceedings of the National Academy of Sciences of the USA. 88:1991;6353-6357.
6. Carbonnet F, Hattab C, Cartron J P, Bertrand O. Kell and Kx, two disulfide-linked proteins of the human erythrocyte membrane are phosphorylated in vivo. Biochemical and Biophysical Research Communications. 247:1998;569-575.
7. Turner A J, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB Journal. 11:1997;355-364.
8. McKerrow J H. Human fibroblast collagenase contains an amino acid sequence homologous to the zinc-binding site of Serratia protease. Journal of Biological Chemistry. 262:1987;5943.
9. Jongeneel C V, Bouvier J, Bairoch A. A unique signature identifies a family of zinc-dependent metallopeptidases. Federation of European Biochemical Societies Letters. 242:1989;211-214.
10. Rawlings N D, Barrett N J. Evolutionary families of metallopeptidases. Barrett A J. Methods in Enzymology. 1995;183-228 Academic Press, San Diego.
11. Vallee B L, Auld D S. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry. 29:1990;5647-5659.
12. Dion N, Le Moual H, Fournie-Zaluski M C. Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2′ residue of substrates and inhibitors. Biochemical Journal. 311:1995;623-627.
13. Dion N, Le Moual H, Crine P, Boileau G. Kinetic evidence that His-711 of neutral endopeptidase 24.11 is involved in stabilization of the transition state. Federation of European Biochemical Societies Letters. 318:1993;301-304.
14. Le Moual H, Dion N, Roques B P. Asp650 is crucial for catalytic activity of neutral endopeptidase 24-11. European Journal of Biochemistry. 221:1994;475-480.
15. Le Moual H, Crine P, Boileau G. Identification of Glu 646 of neutral endopeptidase 24-11 as a zinc binding residue. Matrix Supplement. 1:1992;100.
16. Le Moual H, Beaumont A, Roques B P. Identification of two arginine residues involved in the binding of substrate to neutral endopeptidase 24-11. Matrix Supplement. 1:1992;99.
17. Beaumont A, Barbe B, Le Moual H. Charge polarity reversal inverses the specificity of neutral endopeptidase-24.11. Journal of Biological Chemistry. 267:1992;2138-2141.
18. Bateman R C Jr, Jackson D, Slaughter C A. Identification of the active-site arginine in rat neutral endopeptidase 24.11 (enkephalinase) as arginine 102 and analysis of a glutamine 102 mutant. Journal of Biological Chemistry. 264:1989;6151-6157.
19. Shimada K, Takahashi M, Turner A J, Tanzawa K. Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Biochemical Journal. 315:1996;863-867.
20. Shipp M A, Richardson N E, Sayre P H. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proceedings of the National Academy of Sciences of the USA. 85:1988;4819-4823.
21. Shipp M A, Look A T. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key. Blood. 82:1993;1052-1070.
22. Turner A J, Murphy L J, Medeiros M S, Barnes K. Endopeptidase-24.11 (neprilysin) and relatives. Twenty years on. Suzuki K, Bond J. Intracellular Protein Catabolism. 1996;141-148 Plenum Press, New York.
23. Turner A J, Murphy L J. Molecular pharmacology of endothelin converting enzymes. Biochemical Pharmacology. 51:1996;91-102.
24. Xu D, Emoto N, Giaid A. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485.
25. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. Journal of Biological Chemistry. 270:1995;15262-15268.
26. Lipman M L, Panda D, Bennett H PJ. Cloning of human PEX cDNA - expression, subcellular localization, and endopeptidase activity. Journal of Biological Chemistry. 273:1998;13729-13737.
27. Valdenaire O, Richards J G, Faull R LM, Schweizer A. XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS. Molecular Brain Research. 64:1999;211-221.
28. Lee S, Lin M, Mele A. Proteolytic processing of big endothelin-3 by the Kell blood group protein. Blood. 94:1999;1440-1450.
29. Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proceedings of the National Academy of Sciences of the USA. 86:1989;2863-2867.
30. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, London. 332:1988;411-415.
31. Yanagisawa M, Inoue A, Ishikawa T. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proceedings of the National Academy of Sciences of the USA. 85:1988;6964-6967.
32. Itoh Y, Yanagisawa M, Ohkubo S. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. Federation of European Biochemical Societies Letters. 231:1988;440-444.
33. Webb D J, Monge J C, Rabelink T J. Endothelin: new discoveries and rapid progress in the clinic. Trends in Pharmacological Sciences. 19:1998;5-8.
34. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature, London. 348:1990;730-732.
35. Masaki T, Ninomiya H, Sakamoto A, Okamoto Y. Structural basis of the function of endothelin receptor. Molecular and Cellular Biochemistry. 190:1999;153-156.
36. Sakurai T, Yanagisawa M, Takuwa Y. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature, London. 348:1990;732-735.
37. Baynash A G, Hosoda K, Giaid A. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell. 79:1994;1277-1285.
38. Hosoda K, Hammer R E, Richardson J A. Targeted and natural (Piebald-Lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 79:1994;1267-1276.
39. Kurihara Y, Kurihara H, Suzuki H. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature, London. 368:1994;703-710.
40. Kurihara Y, Kurihara H, Oda H. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. Journal of Clinical Investigation. 96:1995;293-300.
41. Clouthier D E, Hosoda K, Richardson J A. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 125:1998;813-824.
42. Yanagisawa H, Yanagisawa M, Kapur R P. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development. 125:1998;825-836.
43. Hasegawa H, Hiki K, Sawamura T. Purification of a novel endothelin-converting enzyme specific for big endothelin-3. Federation of European Biochemical Societies Letters. 428:1998;304-308.
44. Zelinski T, Coghlan G, Myal Y. Genetic linkage between the Kell blood group system and prolactin-inducible protein loci: provisional assignment of KEL to chromosome 7. Annals of Human Genetics. 55:1991;137-140.
45. Lee S, Zambas E D, Marsh W L, Redman C M. The human Kell blood group gene maps to chromosome 7q33 and its expression is restricted to erythroid cells. Blood. 81:1993;2804-2809.
46. Lee S, Zambas E, Green E D, Redman C. Organization of the gene encoding the human Kell blood group protein. Blood. 85:1995;1364-1370.
47. Lee S, Wu X, Reid M, Redman C. Molecular basis of the K:6,-7[Js(a + b-)]phenotype in the Kell blood group system. Transfusion. 35:1995;822-825.
48. Lee S, Wu X, Son S. Point mutations characterize KEL10, the KEL3, KEL4, and KEL21 alleles, and the KEL17 and KEL11 alleles. Transfusion. 36:1996;490-494.
49. Yazdanbakhsh K, Lee S, Yu Q, Reid M E. Identification of a defect in the intracellular trafficking of a Kell blood group variant. Blood. 94:1999;310-318.
50. Lee S, Wu X, Reid M, Zelinski T, Redman C. Molecular basis of the Kell (K1) phenotype. Blood. 85:1995;912-916.
51. Lee S H, Bennett P R, Overton T. Prenatal diagnosis of Kell blood cell group genotypes: KEL1 and KEL2. American Journal of Obstetrics and Gynecology. 175:1996;455-459.
52. Avent N D, Martin P G. Kell typing by allele-specific PCR (ASP). British Journal of Haematology. 93:1996;728-730.
53. Murphy M T, Fraser R H, Goddard J P. Development of a PCR-based diagnostic assay for the determination of KEL genotype in donor blood samples. Transfusion Medicine. 6:1996;133-137.
54. Spence W C, Maddalena A, Demers D B, Bick D P. Prenatal determination of genotypes Kell and Cellano in at-risk pregnancies. Journal of Reproductive Medicine. 42:1997;353-357.
55. Mifsud N A, Haddad A P, Sparrow R L, Condon J A. Use of polymerase chain reaction-sequence specific oligonucleotide technique for the detection of the K1/K2 polymorphism of the Kell blood group system. Blood. 89:1997;4662-4663.
56. Petty A C, Daniels G L, Tippett P. Application of the MAIEA assay to the Kell blood group system. Vox Sanguinis. 66:1994;216-224.
57. Vengelen-Tyler V, Gonzalez B, Garratty G. Acquired loss of red cell Kell antigens. British Journal of Haematology. 65:1987;231-234.
58. Williamson L M, Poole J, Redman C. Transient loss of proteins carrying Kell and Lutheran red cell antigens during consecutive relapses of autoimmune thrombocytopenia. British Journal of Haematology. 87:1994;805-812.
59. Caine M E, Mueller-Heubach E. Kell sensitization in pregnancy. American Journal of Obstetrics and Gynecology. 154:1986;85-90.
60. Mayne K M, Bowell P J, Pratt G A. The significance of anti-Kell sensitization in pregnancy. Clinical and Laboratory Haematology. 12:1990;379-385.
61. Leggat H M, Gibson J M, Barron S L, Reid M M. Anti-Kell in pregnancy. British Journal of Obstetrics and Gynaecology. 98:1991;162-165.
62. Babinszki A, Lapinski R H, Berkowitz R L. Prognostic factors and management in pregnancies complicated with severe Kell alloimmunization: experiences of the last 13 years. American Journal of Perinatology. 15:1998;695-701.
63. Berkowitz R L, Beyth Y, Sadovsky E. Death in utero due to Kell sensitization without excessive elevation of the delta OD450 value in amniotic fluid. Obstetrics and Gynecology. 60:1982;746-749.
64. Bowman J M, Pollock J M, Manning F A. Maternal Kell blood group alloimmunization. Obstetrics and Gynecology. 79:1992;239-244.
65. Jackson G M, Scott J R. Alloimmune conditions and pregnancy. Baillière's Clinical Obstetrics and Gynaecology. 6:1992;541-563.
66. Parilla B V, Socol M L. Hydrops fetalis with Kell isoimmunization. Obstetrics and Gynecology. 88:1996;730.
67. Vaughan J I, Warwick R, Welch C R, Letsky E A. Anti-Kell in pregnancy. British Journal of Obstetrics and Gynaecology. 98:1991;944-945.
68. Weiner C P, Widness J A. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. American Journal of Obstetrics and Gynecology. 174:1996;547-551.
69. Vaughan J I, Warwick R, Letsky E. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. American Journal of Obstetrics and Gynecology. 171:1994;247-252.
70. Vaughan J I, Manning M, Warwick R M. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. New England Journal of Medicine. 338:1998;798-803.
71. Southcott M JG, Tanner M JA, Anstee D J. The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood. 93:1999;4425-4435.
72. Bertelson C J, Pogo A O, Chaudhuri A. Localization of the McLeod locus (XK) within Xp21 by deletion analysis. American Journal of Human Genetics. 42:1988;703-711.
73. Ho M, Chelly J, Carter N. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell. 77:1994;869-880.
74. Ho M F, Chalmer R M, Davis M B. A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis. Annals of Neurology. 39:1996;672-675.
75. Hanaoka N, Yoshida K, Nakamura A. A novel frameshift mutation in the McLeod syndrome gene in a Japanese family. Journal of the Neurological Sciences. 165:1999;6-9.
76. Francke U, Ochs H D, de Martinville B. Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. American Journal of Human Genetics. 37:1985;250-267.
77. Frey D, Machler M, Seger R. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood. 71:1988;252-255.
78. Redman C M, Marsh W L, Scarborough A. Biochemical studies on McLeod phenotype red cells and isolation of Kx antigen. British Journal of Haematology. 68:1988;131-136.
79. Carbonnet F, Hattab C, Callebaut I. Kx, a quantitatively minor protein from human erythrocytes, is palmitoylated in vivo. Biochemical and Biophysical Research Communications. 250:1998;569-574.
80. Redman C M, Avellino G, Pfeffer S R. Kell blood group antigens are part of a 93 000-dalton red cell membrane protein. Journal of Biological Chemistry. 261:1986;9521-9525.
81. Khamlichi S, Bailly P, Blanchard D. Purification and partial characterization of the erythrocyte Kx protein deficient in McLeod patients. European Journal of Biochemistry. 228:1995;931-934.
82. Carbonnet F, Hattab C, Collec E. Immunochemical analysis of the Kx protein from human red cells of different Kll phenotypes using antibodies raised against synthetic peptides. British Journal of Haematology. 96:1997;857-863.
83. Russo D, Redman C, Lee S. Association of XK and Kell blood group proteins. Journal of Biological Chemistry. 273:1998;13950-13956.
84. Russo D C, Lee S, Reid M, Redman C M. Topology of Kell blood group protein and the expression of multiple antigens by transfected cells. Blood. 84:1994;3518-3523.
85. Russo D, Lee S, Redman C. Intracellular assembly of Kell and XK blood group proteins. Biochimica et Biophysica Acta. 1461:1999;10-18.
86. Daniels G L, Weinauer F, Stone C. A combination of the effects of rare genotypes at the XK and KEL blood group loci results in absence of Kell system antigens from the red blood cells. Blood. 88:1996;4045-4050.
87. Allen F H Jr, Krabbe S MR, Corcoran P A. A new phenotype (McLeod) in the Kell blood group system. Vox Sanguinis. 6:1961;555-560.
88. Wimer B M, Marsh W L, Taswell H F, Galey W R. Haematological changes associated with the McLeod phenotype of the Kell blood group system. British Journal of Haematology. 36:1977;219-224.
89. Symmans W A, Shepherd C S, Marsh W L. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. British Journal of Haematology. 42:1979;575-583.
90. Marsh W L, Marsh N J, Moore A. Elevated serum creatine phosphokinase in subjects with McLeod syndrome. Vox Sanguinis. 40:1981;403-411.
91. Swash M, Schwartz M S, Carter N D. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain. 106:1983;717-733.
92. Danek A, Uttner I, Vogl T. Cerebral involvement in McLeod syndrome. Neurology. 44:1994;117-120.
93. Witt T N, Danek A, Reiter M. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. Journal of Neurology. 239:1992;302-306.
94. Jeren-Strujic B, Jeren T, Thaller N. A case of McLeod syndrome with chronic renal failure. Blood Purification. 16:1998;336-340.
95. Hardie R J. Acanthocytosis and neurological impairment - a review. Quarterly Journal of Medicine. 71:1989;291-306.